Skip to Content

Trizytek Approval Status

Trizytek (liprotamase) is a non-porcine derived enzyme replacement therapy in development for patients with pancreatic insufficiency. The FDA issued a complete response letter for liprotamase in April 2011.

Development Status and FDA Approval Process for Trizytek

Apr 18, 2011Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
Jan 13, 2011Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
Nov 17, 2008Altus Pharmaceuticals Reaffirms Plan to Submit New Drug Applicationfor Trizytek Approval

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.